PD-L1 IHC 22C3 pharmDx

"PD-L1 IHC 22C3 pharmDx is a laboratory test which the doctors can employ in identifying the protein programmed cell death ligand 1 (PD-L1) in tumor tissue obtained from patients with lung and gastric cancer. This supplement enlarges the indications for use for this test to comprise, determining whether patients with cervical cancer are eligible for treatment with the medicine (pembrolizumab).
PD-L1 IHC 22C3 pharmDx Advancing Immunotherapy Options Cytotoxic T cells work to identify as well as eliminate infected cells and tumor cells from the body. To lessen the damage to surrounding tissue, normal cells distinguish themselves by expressing a protein signal called PD-L1 (programmed death ligand 1). This PD-L1 signal is a stop sign developed to avoid elimination of normal cells by cytotoxic T cells. T cells detect the PD-L1 signal through a receptor called PD-1 (programmed death receptor 1). Some tumors can also deliver the PD-L1 signal to mimic normal cells and escape elimination. Anti-PD-1 therapy operates by blocking the PD-1/PD-L1 interaction. PD-L1 expression may be associated with patient benefit from anti-PD-1 therapy."